Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka(Keio University Hospital), Dianna J. Magliano(Monash University), Matthias Saathoff(University of Manitoba), Johan Bodegård(Statistics Norway), Bendix Carstensen(Steno Diabetes Centers), Reinhard W. Holl(Deutsches Diabetes-Zentrum e.V.), Anna Norhammar, Jenni Ilomäki(Monash University), Jonathan E. Shaw(St Mary's Hospital), Su‐Yen Goh(Singapore General Hospital), Eric Wittbrodt, Dae Jung Kim(Kingston Health Sciences Centre), Avraham Karasik(Maccabi Institute for Health Services Research), Suzanne V. Arnold(Saint Luke's Health System), Marit E. Jørgensen(Ilisimatusarfik), John Wilding(University of Liverpool), Filip Surmont(AstraZeneca (United Kingdom)), Mikhail Kosiborod(AstraZeneca (Brazil)), Hanne Løvdal Gulseth, Hungta Chen(AstraZeneca (United Kingdom)), Carolyn S.P. Lam(University of Glasgow), Esther Bollow, Kamlesh Khunti(University of Leicester), Matthew A. Cavender, Betina T. Blak, Navdeep Tangri(Orthopaedic Innovation Centre), Marcus Thuresson(Statisticon (Sweden)), Peter Fenici(AstraZeneca (United Kingdom)), Luis A. Garcı́a Rodrı́guez(University of Colorado Boulder), Chern-En Chiang(National Yang Ming Chiao Tung University), Kåre I. Birkeland(Oslo University Hospital), Josep Franch‐Nadal(Tel Aviv University)
Cited by 93
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k